




## RESEARCH ARTICLE

# A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Pietro Iaffaldano<sup>1</sup> , Giuseppe Lucisano<sup>2</sup>, Tommaso Guerra<sup>1</sup>, Damiano Paolicelli<sup>1</sup>, Emilio Portaccio<sup>3</sup>, Matilde Inglese<sup>4,5</sup>, Matteo Foschi<sup>6</sup>, Francesco Patti<sup>7</sup>, Franco Granella<sup>8</sup>, Silvia Romano<sup>9</sup> , Paola Cavalla<sup>10</sup>, Giovanna De Luca<sup>11</sup>, Paolo Gallo<sup>12</sup>, Paolo Bellantonio<sup>13</sup>, Antonio Gallo<sup>14</sup>, Sara Montepietra<sup>15</sup>, Alessia Di Sapio<sup>16</sup>, Marika Vianello<sup>17</sup>, Rocco Quatralo<sup>18</sup>, Daniele Spitaleri<sup>19</sup>, Raffaella Clerici<sup>20</sup>, Valentina Torri Clerici<sup>21</sup>, Eleonora Cocco<sup>22</sup>, Vincenzo Brescia Morra<sup>23</sup>, Girolama Alessandra Marfia<sup>24</sup>, Vincenzo Daniele Boccia<sup>4</sup>, Massimo Filippi<sup>25</sup> , Maria Pia Amato<sup>3</sup>, Maria Trojano<sup>1</sup> & on behalf of the Italian MS Register

<sup>1</sup>Department of Translational Biomedicine and Neurosciences, University of Bari Aldo Moro, Bari, Italy

<sup>2</sup>CORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy

<sup>3</sup>Department of Neurofarba, University of Florence, Florence, Italy

<sup>4</sup>Dipartimento Di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno - Infantili (DINOEMI), Università di Genova, Genoa, Italy

<sup>5</sup>IRCCS Ospedale Policlinico San Martino, Genoa, Italy

<sup>6</sup>Department of Neuroscience, Multiple Sclerosis Center-Neurology Unit, S. Maria delle Croci Hospital of Ravenna, AUSL Romagna, Ravenna, 48121, Italy

<sup>7</sup>Dipartimento di Scienze Mediche e Chirurgiche e Tecnologie Avanzate, GF Ingrassia, Sez. Neuroscienze, Centro Sclerosi Multipla, Università di Catania, Catania, Italy

<sup>8</sup>Unit of Neurosciences, Department of Medicine and Surgery, University of Parma, Parma, Italy

<sup>9</sup>Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy

<sup>10</sup>Multiple Sclerosis Center and 1 Neurology Unit, Department of Neurosciences and Mental Health, AOU Città della Salute e della Scienza di Torino via Cherasco 15, Torino, 10126, Italy

<sup>11</sup>Centro Sclerosi Multipla, Clinica Neurologica, Policlinico SS. Annunziata, Chieti, Italy

<sup>12</sup>Department of Neurosciences, Multiple Sclerosis Centre-Veneto Region (CeSMuV), University Hospital of Padua, Padua, Italy

<sup>13</sup>Unit of Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli, Italy

<sup>14</sup>Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy

<sup>15</sup>Neurology Unit, Neuromotor and Rehabilitation Department, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy

<sup>16</sup>Regional Referral MS Center, Neurological Unit, Univ. Hospital San Luigi, Orbassano, Italy

<sup>17</sup>Unit of Neurology, Cà Foncello Hospital, Treviso, Italy

<sup>18</sup>Ambulatorio Sclerosi Multipla - Divisione di Neurologia, Ospedale dell'Angelo, Mestre, Italy

<sup>19</sup>Department of Neurology, AORN San G. Moscati di Avellino, Avellino, Italy

<sup>20</sup>Centro ad Alta Specializzazione per la diagnosi e la cura della sclerosi multipla, Ospedale Generale di zona Valduce, Como, Italy

<sup>21</sup>Foundation Neurological Institute C. Besta, Milan, Italy

<sup>22</sup>Department of Medical Science and Public Health, Centro Sclerosi Multipla, University of Cagliari, Cagliari, Italy

<sup>23</sup>Department of Neuroscience (NSRO), Multiple Sclerosis Clinical Care and Research Center, Federico II University, Naples, Italy

<sup>24</sup>Multiple Sclerosis Clinical and Research Unit, University Hospital of Rome Tor Vergata, Rome, Italy

<sup>25</sup>Neurology Unit and MS Center, IRCCS San Raffaele Scientific Institute, Milan, Italy

## Correspondence

Maria Trojano, School of Medicine, University "Aldo Moro" Bari, Piazza Giulio Cesare 11, Bari 70124, Italy. Tel: 080-5478555; Fax: 080-5478755; E-mail: [maria.trojano@uniba.it](mailto:maria.trojano@uniba.it)

Received: 15 March 2024; Revised: 17 May 2024; Accepted: 23 May 2024

doi: 10.1002/acn3.52118

## Abstract

**Objective:** No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) events are currently available. We aimed to compare the risk of achieving first 6 months confirmed PIRA and RAW events and irreversible Expanded Disability Status Scale (EDSS) 4.0 and 6.0 in a cohort of naïve patients treated with natalizumab or ocrelizumab from the Italian Multiple Sclerosis Register. **Methods:** Patients with a first visit within 1 year from onset, treated with natalizumab or ocrelizumab, and  $\geq 3$  visits were extracted. Pairwise propensity score-matched analyses were performed. Risk of reaching the first PIRA, RAW, and EDSS 4.0 and 6.0 events were estimated using multivariable Cox proportional hazards models. Kaplan–Meier curves were used to show

cumulative probabilities of reaching outcomes. **Results:** In total, 770 subjects were included (natalizumab = 568; ocrelizumab = 212) and the propensity score-matching retrieved 195 pairs. No RAW events were found in natalizumab group and only 1 was reported in ocrelizumab group. A first PIRA event was reached by 23 natalizumab and 25 ocrelizumab exposed patients; 7 natalizumab- and 10 ocrelizumab-treated patients obtained an irreversible EDSS 4.0, while 13 natalizumab- and 15 ocrelizumab-treated patients reached an irreversible EDSS 6.0. No differences between the two groups were found in the risk (HR, 95%CI) of reaching a first PIRA (1.04, 0.59–1.84;  $p = 0.88$ ) event, an irreversible EDSS 4.0 (1.23, 0.57–2.66;  $p = 0.60$ ) and 6.0 (0.93, 0.32–2.68;  $p = 0.89$ ). **Interpretation:** Both medications strongly suppress RAW events and, in the short term, the risk of achieving PIRA events, EDSS 4.0 and 6.0 milestones is not significantly different.

## Introduction

The overlapping of focal recurring inflammation, more widespread inflammatory processes, and neurodegeneration underlines the course of multiple sclerosis (MS) during all stages of the disease, challenging the classic described phenotypes.<sup>1,2</sup> There is a mutual contribution of progression independent of relapse activity (PIRA) and relapse-related worsening (RAW) events to progressive disability accrual since the disease onset, requiring an optimal timing of diagnosis and the appropriate disease-modifying therapy (DMT) to reduce as much as possible the disability burden.<sup>3–6</sup> Relapses remain a crucial determinant of disability accumulation, playing a role both in the short and long term,<sup>7,8</sup> and age is configured as the main risk factor associated with the occurrence of PIRA events.<sup>9</sup>

Exposure to new highly effective (HE) DMTs has been proven to have greater efficacy in reducing the accumulation of disability resulting from PIRA and RAW,<sup>2,9</sup> in comparison with moderate effective treatments. However, reliable comparative effectiveness studies between HE DMTs are scarce in the MS literature landscape<sup>10</sup> and their effect on PIRA needs to be better clarified. Ocrelizumab (OCR) and natalizumab (NTZ) demonstrated a strong anti-inflammatory activity as HE DMTs, changing the prognosis of MS patients.<sup>11</sup> Studies based on large cohorts from disease registries demonstrated to be essential in exploring potential disease outcomes and DMT effectiveness over the medium and long term in real-life settings.<sup>12</sup>

In a large real life-cohort of naïve relapsing–remitting MS patients (RRMS) from the Italian MS and Related Disorders Register (I-MS&RD),<sup>13</sup> we compared the risk of achieving the first 6 months confirmed PIRA and RAW events and irreversible Expanded Disability Status Scale (EDSS) 4.0 and 6.0 between patients treated with NTZ and those treated with OCR.

## Materials and Methods

### Data extraction

This was a study based on data extracted from the I-MS&RD. The I-MS&RD was approved by the ethical committee at the “Azienda Ospedaliero – Universitaria – Policlinico of Bari” (Study REGISTRO SM001 – approved on 8 July 2016) and by local ethics committees in all participating centers. Patients signed an informed consent that allows to collect and use their clinical data for research purposes. According to the Registry rules, the Scientific Committee of the I-MS&RD granted the approval to conduct this project and extract and use the registry data. Data extraction was executed in May 2023. A minimum dataset of demographic and clinical characteristic from the I-MS&RD was considered.

### Study population and outcome definitions

RRMS patients with a first visit within 1 year from disease onset, a first DMT prescription with NTZ or OCR after 31 December 2017, and  $\geq 3$  EDSS score evaluations were included in the analysis.

Outcomes were defined as following:

- Confirmed disability accrual (CDA) was defined as a confirmed 6-month disability increase from study baseline, measured by EDSS (increase  $\geq 1.5$  points with baseline EDSS = 0;  $\geq 1.0$  point with baseline EDSS  $> 1.0$ , and  $< 5.5$ ;  $\geq 0.5$  point with baseline EDSS  $> 6.0$ ). Date of CDA was assigned at the first EDSS when an increase was registered.
- RAW was defined as a CDA event in which the initial disability increase from study baseline occurred within 90 days or earlier after or 30 or earlier days before the onset of a relapse.

- PIRA was defined as a CDA event occurring more than 90 days after and more than 30 days before the onset of a relapse.
- Irreversible EDSS 4.0 and 6.0: achievement of EDSS scores greater than or equal to 4.0 or 6.0 followed by never lower EDSS ratings in all the subsequent follow-up visits.

### Study method and statistical analysis

The following variables were included in the dataset: age (in years), gender (male and female), type of onset (monofocal/multifocal/not known), number of relapses (0, 1,  $\geq 2$ ), IgG oligoclonal bands (OCBs) in the CSF (presence/absence/not known), number of EDSS evaluations with complete information regarding functional scores (FS), and start and end dates of all the administered DMTs.

The inclusion of the “not known” category was necessary to ensure the inclusion of all the selected patients in the multivariate analysis. Furthermore, indicating the number of EDSS assessments is functional to matching subjects with a comparable number of visits.

In descriptive analyses, categorical data were expressed as frequency and proportion. Continuous data were expressed as mean (SD).

To mitigate the impact of potential biases, pairwise propensity score (PS)-matched analyses 1:1 based on baseline covariates at the start of the first NTZ or OCR dose, were performed, without replacement. The quality of the procedure in each pair of matched cohorts was assessed with absolute standardized mean difference (SMD), considering SMD less than 10% acceptable, as absolute value.

PS-matched analysis derived from a multivariable logistic regression model to estimate patient's probability of being assigned to OCR treatment. Considering the matched cohort with balanced characteristics, the risk of reaching the first PIRA and RAW events and irreversible EDSS 4.0 and 6.0 were estimated using multivariable Cox proportional hazards models (CHM). Results of CHM were represented as hazard ratio and 95% confidence interval, HR (95% CI). Kaplan–Meier (KM) curves were used to show the cumulative probabilities of reaching the outcomes.

Patients included in the cohort were followed from the start of NTZ or OCR to the moment of the occurrence of the outcome considered, or to the last visit, or to the treatment switch.

A  $p$ -value  $< 0.05$  was considered statistically significant. Analyses were performed using SAS Software Release 9.4 (SAS Institute, Cary, NC).

## Results

Clinical data of 81,123 patients were available in the I-MS&RD at the time of data extraction. After applying the inclusion criteria, we retrieved a cohort of 770 RRMS patients, of which 568 were treated with NTZ and 212 with OCR. The PS matching procedure subsequently resulted in 195 pairs of patients. (Fig. 1) Baseline characteristics of the cohort before and after PS matching are reported in Table 1. Patients treated with NTZ, before the PS matching, were younger at DMT start (mean (SD): 30.19 (10.15)<sup>10–15</sup> years vs. 36.22 (11.23)), less disabled (mean (SD) EDSS score: 1.92 (1.31) vs. 2.51 (1.51)), more frequently females (65.49% vs. 58.02%), compared to patients treated with OCR in term of SMD values. After the matching procedure, considering the SMD values, the groups resulted balanced and comparable, with an age at DMT start of about 35 years, female gender in 60% of patients, monofocal onset in about 72% patients, OCBs presence in about 91% patients, EDSS score of about 2.5, number of EDSS evaluations of about 4.5, and at least one relapse in about 32% patients.

Median follow-up (IQR) after the treatment start was 1.63 (0.87–2.72) for NTZ group and 1.60 (0.80–2.68) years for OCR group.


A first PIRA event was reached by 23 (11.79%) NTZ-exposed patients and 25 (12.82%) OCR exposed patients. No RAW events were found in the NTZ group and only 1 RAW event was reported in the OCR group. An irreversible EDSS 4.0 was reached by 7 (4.14%) NTZ-treated patients and 10 (5.85%) OCR-treated patients, and an irreversible EDSS 6.0 was reached by 13 (6.67%) NTZ-treated patients and 15 (7.69%) OCR-treated patients. (Fig. 2).

KM curves for the probabilities of reaching the outcomes are shown in the Figure 3. KM for RAW events were not outlined because there were no events to display.

No differences between the two groups were found in the risk (HR, 95%CI) of reaching a first PIRA (Fig. 3A) (1.04, 0.59–1.84;  $p = 0.88$ ) event, and irreversible EDSS 4.0 (Fig. 3B) (1.23, 0.57–2.66;  $p = 0.60$ ) and EDSS 6.0 (0.93, 0.32–2.68;  $p = 0.89$ ) (Fig. 3C).

Finally, 27 (13.85%) and 8 (4.10%) ( $p = 0.001$ ) patients switched to another DMT, in NTZ- and OCR-treated groups, respectively. In the NTZ-treated switcher group, 9 patients (33.33%) switched to OCR.

In the OCR-treated group, 3 patients switched to glatiramer acetate for pregnancy planning, 1 to NTZ for disease progression, and 4 to dimethyl fumarate due to a de-escalation strategy. In the NTZ group, we identified 20 patients switched for adverse events, with 2 cases of



**Figure 1.** Flowchart of the patients' selection procedure. I-MS&RD, Italian MS and Related Disorders Register; NTZ, natalizumab; OCR, ocrelizumab.


**Table 1.** Baseline clinical and demographic characteristics of NTZ- and OCR-treated RRMS patients before and after PS matching procedure.

Variable	NTZ (n = 568)	OCR (n = 212)	SMD	NTZ (n = 195)	OCR (n = 195)	SMD
Age at DMT start, mean (SD), years	30.19 (10.15)	36.22 (11.23)	56.4	35.03 (10.61)	35.21 (10.65)	1.7
Female, n (%)	372 (65.49)	123 (58.02)	-15.4	114 (58.46)	117 (60.00)	3.1
Type of clinical onset of the disease						
Monofocal	425 (74.82)	150 (70.75)	-9.2	144 (73.85)	140 (71.79)	-4.6
Multifocal	93 (16.37)	36 (16.98)		26 (13.33)	34 (17.44)	
Not known	50 (8.80)	26 (12.26)		25 (12.82)	21 (10.77)	
OCBs presence in CSF, n (%)						
Absent	19 (3.35)	11 (5.19)	9.1	9 (4.62)	10 (5.13)	2.4
Present	219 (38.56)	106 (50.00)		93 (47.69)	95 (48.72)	
Not known	330 (58.10)	95 (44.81)		93 (47.69)	90 (46.15)	
EDSS at DMT start, mean (SD)	1.92 (1.31)	2.51 (1.51)	41.6	2.35 (1.43)	2.32 (1.32)	-1.7
Number of EDSS score evaluations, mean (SD)	4.67 (2.55)	4.47 (2.40)	-8.1	4.44 (2.45)	4.48 (2.42)	1.9
Number of relapses prior DMT start, n (%)						
0	376 (66.20)	145 (68.40)	4.7	121 (62.05)	132 (67.69)	11.8
1	152 (26.76)	55 (25.94)		61 (31.28)	51 (26.15)	
≥2	40 (7.04)	12 (5.66)		13 (6.67)	12 (6.15)	


Abbreviations: DMT, disease-modifying therapy; OCBs, oligoclonal bands; CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale.

elevated levels of serum transaminases and 18 cases of suspension due to JCV antibody positivity, and within this group 8 patients switched to cladribine, 7 to OCR, 1 to siponimod, 1 to dimethyl fumarate, 1 to teriflunomide, 1 to interferon beta-1a, and 1 to glatiramer acetate; 4

patients suspended therapy due to allergic reactions, switching to cladribine, OCR, alemtuzumab and dimethyl fumarate; 1 patient switched to siponimod due to secondary progressive MS conversion, 1 to dimethyl fumarate for pregnancy planning and 1 to OCR for patient choice.



**Figure 2.** Number of patients reaching a first PIRA event, irreversible EDSS 4.0 and 6.0 in NTZ and OCR treatment groups of the matched cohort. NTZ, natalizumab; OCR, ocrelizumab; PIRA, progression independent of relapse activity; EDSS, Expanded Disability Status Scale.



**Figure 3.** Cumulative incidence of PIRA (A), irreversible EDSS 4.0 (B) and irreversible EDSS 6.0 (C) in NTZ- and OCR-treated patients. NTZ, natalizumab; OCR, ocrelizumab; PIRA, progression independent of relapse activity; EDSS, Expanded Disability Status Scale; HR, hazard ratio; CI, confidence interval.

## Discussion

To our knowledge, this is the first study aimed at comparing the effect of NTZ and OCR on the risk of achieving the first 6-month confirmed PIRA and RAW events and severe EDSS disability milestones in a large real-life cohort of naïve RRMS patients.

All the newly approved HE DMTs have demonstrated an excellent profile of effectiveness in reducing clinical and radiological disease activity, over the years.<sup>11</sup> Some recent meta-analyses have developed an effectiveness ranking for all available DMTs, placing NTZ and OCR at comparable levels.<sup>14,15</sup> NTZ proved to be highly effective in RRMS treatment both in clinical trials and real-world settings with a well-established safety profile, leading to a significant improvement in the control of

disease activity.<sup>16,17</sup> Growing evidence suggests that OCR has a strong anti-inflammatory action, with an almost complete suppression of clinical and radiological disease activity, and a significant effect in slowing the progression of disability accrual in RR and progressive MS.<sup>18,19</sup>

A recent study<sup>20</sup> compared, in a real-world PS-matched cohort of RRMS patients, the effectiveness of NTZ and OCR using the NEDA-3 as outcome. After 30 months of follow-up, NEDA-3 was reached by 53.1% in the OCR group and by 36.1% in the NTZ group, the treatment with OCR was associated with a lower risk of relapse, while the reduction of serum NFL levels did not differ between the two treatment groups. Another study showed that, in RRMS who switched from NTZ to dimethyl fumarate or fingolimod or OCR, the switch to OCR was

associated with the lowest ARR and discontinuation rates and the longest time to first relapse.<sup>21</sup>

To date, the assessment of DMT effect on PIRA events has not been sufficiently investigated.<sup>22,23</sup>

PIRA events, especially those that occurred early in the disease course, have been demonstrated to be predictors of unfavorable long-term disability prognosis.<sup>24</sup> Therefore, a timely and prolonged treatment with the appropriate DMT is also primarily aimed at reducing the occurrence of PIRA events.<sup>2,9</sup> The superiority of OCR over interferon beta 1a in reducing PIRA, has already been reported in OPERA 1 and 2 trials.<sup>4</sup> OCR proved an all-rounder beneficial effect on cognitive function, fatigue, and quality of life of MS patients, considering composite clinical measures and magnetic resonance imaging (MRI) and fluid biomarkers to assess disease progression.<sup>19</sup>

Currently, the pathophysiological substrate of PIRA remains incompletely characterized.<sup>25,26</sup> The effect on PIRA of NTZ and OCR, with completely different mechanisms of action but a common strong anti-inflammatory effect, could be due to the suppression of inflammatory pathological processes in the “smoldering” MS lesions.<sup>2,6</sup> Despite predicted effects on inflammatory networks related to microglia in chronic active lesions, anti-CD20 therapies failed to fully resolve paramagnetic rim lesions after a 2-year MRI follow-up in a recent study.<sup>27</sup> These findings highlight the necessity of better identifying PIRA’s pathological substrates to further evaluate appropriate treatment strategies.

Our results demonstrate that both OCR and NTZ strongly suppress RAW events and have a similar impact on PIRA in naïve RRMS patients, confirming that an early access to HE DMTs<sup>28–30</sup> may result in a beneficial effect on the accumulation of neurological damage, dependent and independent from relapses, early in the disease course.<sup>31,32</sup>

In OPERA I/II, in patients treated with OCR, PIRA events were the main contributors to both 12-week and 24-week CDA after 96 weeks (147 out of 167 [88%] and 115 out of 129 [89%]) and only a minority presented RAW events (29.7%).<sup>4</sup> However, this pooled analysis of two randomized clinical trials (RCTs) used a composite CDA definition, including EDSS alongside with timed 25-foot walk and 9-hole peg test evaluations. Furthermore, considering the limitations of a comparison between our cohort and Kappos’s, baseline data resulted similar in terms of age, sex, EDSS and number of relapses; however, in the pooled analysis only 73.3% of patients were treatment naïve.

Currently, to our knowledge there is no data about PIRA in RCTs populations of NTZ-treated patients.

A few limitations of our study should be taken into account. As with previous retrospective observational studies, incomplete or inaccurate data entered in the register must be acknowledged.

The lack of long-term follow-up has to be considered and the validation of these results over the long-term will constitute a crucial point of future analysis. Although patients with less than 1 year of follow-up might not have greatly contributed to the 6-month confirmed PIRA evaluation, it is important to underline that we selected a cohort of closely monitored patients with at least three EDSS evaluations.

Moreover, as part of the data interpretation process, we also ran an analysis of the power calculation for equivalence study to assess limitations of this comparison of the two DMTs. Although the sample size calculation is not required in observational studies, we hypothesized several scenarios and calculated the necessary patient count to obtain the higher statistical power of 0.80. The number of patients to include per group would be 443 for a difference and 608 for an equivalence analysis, 439 for a superiority and 281 for a non-inferiority analysis. In our study, considering a cumulative incidence of 0.31 and 0.40 respectively for NTZ and OCR cohort, a power of 0.46 have been ensured with a sample size of 195 patients per group. With this cohort, the power is 0.38 for an equivalence study, 0.66 for a superiority, and 0.50 for a non-inferiority analysis. Therefore, a possible explanation of the absence of differences in PIRA outcomes between OCR and NTZ could be related to the sample size, too small to detect a difference.

In the definition of CDA events, we considered solely the EDSS score: although MRI features are considered a crucial prognostic factor and radiological activity is a cornerstone in defining the disease burden, we could not include MRI data because of the lack of a systematic acquisition of these data in the I-MS&RD. Furthermore, in comparison with RCTs, in this real-world study we are unable to account for potential confounders that could have affected results.

Despite all these considerations, our study used the large and validated database of the I-MS&RD to compare the impact of two of HE DMTs on PIRA and RAW events, so far not available in MS literature.

In conclusion, our results confirm that both OCR and NTZ effectively eliminate RAW events in RRMS patients. In the short term, the number and risk of PIRA, EDSS 4.0 irreversible and EDSS 6.0 events were not significantly different between the two treated groups. A longer follow-up and a larger cohort will be essential to confirm data on the effects of NTZ and OCR especially on disability progression outcomes.

## Acknowledgments

None.

## Funding Information

The present work received no specific funding.

## Conflict of Interest

The authors report no conflicts of interest with respect to the contents of the current study, but note that the patients in the study were treated with a number of disease-modifying drugs and that authors have received advisory board, membership, speakers honoraria, travel support, research grants, consulting fees, or clinical trial support from the manufacturers of those drugs, including Actelion, Allergan, Almirall, Alexion, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Forward Pharma, Ipsen, Medday, Merck, Mylan, Novartis, Sanofi, Roche, Teva, and their local affiliates.

## Author Contributions

PI, TG, GL, and MT: conception and design of the study, acquisition and analysis of data, drafting the manuscript and figures; DP, EP, MI, MF, FP, FG, SR, PC, GDL, PG, PB, AG, SM, ADS, MV, RQ, DS, RC; VTR, EC, VBM, AGM, DVB, MF, and MPA: data acquisition and drafting a significant portion of the manuscript.

## Data Availability Statement

Anonymized data will be shared on reasonable request from a qualified investigator.

## References

- Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. *Brain*. 2022;145(9):3147-3161.
- Portaccio E, Bellinva A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. *Brain*. 2022;145(8):2796-2805.
- University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, et al. Silent progression in disease activity-free relapsing multiple sclerosis. *Ann Neurol*. 2019;85(5):653-666.
- Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. *JAMA Neurol*. 2020;77(9):1132-1140.
- Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. *Am J Med*. 2020;133(12):1380-1390.e2.
- Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the 'real MS'. *Ther Adv Neurol Disord*. 2022;15:17562864211066751.
- Jokubaitis VG, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Ann Neurol*. 2016;80(1):89-100.
- Koch-Henriksen N, Sørensen PS, Magyari M. Relapses add to permanent disability in relapsing multiple sclerosis patients. *Mult Scler Relat Disord*. 2021;53:103029.
- Iaffaldano P, Portaccio E, Lucisano G, et al. Multiple sclerosis progression and relapse activity in children [published correction appears in *JAMA Neurol*. 2024;81(1):88]. *JAMA Neurol*. 2024;81(1):50-58.
- Tur C, Kalincik T, Oh J, et al. Head-to-head drug comparisons in multiple sclerosis: urgent action needed. *Neurology*. 2019;93(18):793-809.
- Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion [published correction appears in *J Neurol*. 2022;269(12):6690-6691]. *J Neurol*. 2022;269(10):5382-5394.
- Trojano M, Kalincik T, Iaffaldano P, Amato MP. Interrogating large multiple sclerosis registries and databases: what information can be gained? *Curr Opin Neurol*. 2022;35(3):271-277.
- Trojano M, Bergamaschi R, Amato MP, et al. The Italian multiple sclerosis register [published correction appears in *Neurol Sci*. 2019;40(4):907]. *Neurol Sci*. 2019;40(1):155-165.
- Giovannoni G, Lang S, Wolff R, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. *Neurol Ther*. 2020;9(2):359-374.
- Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. *Autoimmun Rev*. 2021;20(6):102826.
- Correia I, Batista S, Galego O, et al. Long-term effectiveness and safety of natalizumab in a Portuguese population. *Int Immunopharmacol*. 2017;46:105-111.
- Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri observational program (TOP). *J Neurol Neurosurg Psychiatry*. 2020;91(6):660-668.
- Pontieri L, Blinkenberg M, Bramow S, et al. Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study. *Eur J Neurol*. 2022;29(2):496-504.
- Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does Ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers. *Neurotherapeutics*. 2022;19:1216-1228.

20. Pape K, Rolfes L, Steffen F, et al. Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched study. *Ther Adv Neurol Disord*. 2022;15:17562864221142924.
21. Zhu C, Kalincik T, Horakova D, et al. Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation. *JAMA Neurol*. 2023;80(7):739-748.
22. Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. *Nat Rev Drug Discov*. 2019;18(12):905-922.
23. Granziera C, Derfuss T, Kappos L. Time to change the current clinical classification of multiple sclerosis? *JAMA Neurol*. 2023;80(2):128-130.
24. Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, et al. Association of Early Progression Independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. *JAMA Neurol*. 2023;80(2):151-160.
25. Sharrad D, Chugh P, Slee M, Bacchi S. Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review. *Mult Scler Relat Disord*. 2023;78:104899.
26. Cagol A, Schaedelin S, Barakovic M, et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. *JAMA Neurol*. 2022;79(7):682-692.
27. Maggi P, Bulcke CV, Pedrini E, et al. B cell depletion therapy does not resolve chronic active multiple sclerosis lesions. *EBioMedicine*. 2023;94:104701.
28. He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol*. 2020;19(4):307-316.
29. Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. *Ther Adv Neurol Disord*. 2021;14:17562864211019574.
30. Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different National Strategies. *JAMA Neurol*. 2021;78(10):1197-1204.
31. Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-Naïve individuals with relapsing-remitting multiple sclerosis. *CNS Drugs*. 2022;36(12):1285-1299.
32. Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. *J Neurol*. 2022;269(3):1670-1677.